Cancer biosensors are analytical devices that combine a biological recognition element with a physicochemical detector to identify cancer-associated biomarkers. Their underlying measurement principle will be familiar to engineers: a target is recognized, that interaction produces a detectable change, and a transducer converts the change into a readable signal. Applied to clinical samples, this approach may support sensitive biomarker measurement and point-of-care testing, while offering a route to detecting several targets in parallel.
Why cancer biomarker detection matters
Cancer involves complex genetic and epigenetic changes that can affect cellular signaling as a disease develops. Biomarkers—molecules such as proteins, nucleic acids, metabolites or hormones—can provide information about these changes. Their roles differ: diagnostic biomarkers help detect disease, prognostic biomarkers provide information about its course or recurrence, and predictive biomarkers can indicate likely response to treatment.
Conventional diagnostic methods, including imaging and biopsy, have limitations in early detection. Laboratory techniques such as enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR) are also used to identify biomarkers, but the source review notes that these approaches may involve costly reagents, take time and rely on manual procedures. They are not inherently suited to continuous monitoring. Because cancer may involve multiple molecular events, measuring more than one biomarker can also be important for diagnosis and prognosis.
How cancer biosensors turn recognition into a signal
A biosensor has two central elements: a biorecognition component and a transducer. Recognition components can include antibodies, aptamers or nucleic-acid probes that bind to a target. The transducer detects a resulting physical or chemical change and converts it into a signal that can be measured or displayed.
The choice of transducer shapes how the measurement is made. Biosensor formats described for cancer detection include electrochemical, optical, mass-sensitive and calorimetric systems. These approaches are not interchangeable: each measures a different signal, and the best fit depends on the target, sample and intended use. The broader engineering objective is to produce a useful, consistent reading from a biological interaction that may be difficult to observe directly.
Major biosensor approaches
Electrochemical biosensors
Electrochemical biosensors are widely used in the field and are valued in the review for their small size, portability, relative affordability and ease of use. They measure electrical properties associated with target recognition. Three common formats are:
- Amperometric: measures current associated with oxidation-reduction reactions. DNA hybridization and antibody-based immunosensors are among the recognition approaches described for cancer targets.
- Potentiometric: measures a change in electrical potential, including responses produced by ion-selective electrodes when molecular recognition occurs.
- Impedimetric or conductometric: measures changes in impedance or conductivity associated with a sensing event.
Electrochemical affinity sensors can be designed to recognize specific proteins, antigens or genetic sequences. The review also describes sensor arrays in which individual transducers are functionalized for different targets, an approach that can support multi-marker measurement. Such designs make parallel detection a relevant development goal, rather than assuming one marker can represent every molecular feature of a cancer.
Optical biosensors
Optical formats measure changes in light, using techniques such as fluorescence, luminescence, colorimetry or interferometry. Photonic-crystal sensors, for example, can register changes in reflected light when molecules or cells bind to or dissociate from a sensor surface. The review discusses optical sensing for observing changes in breast tumor-cell proliferation and apoptosis during exposure to a treatment, as well as light-based approaches investigated for throat cancer detection.
Mass-sensitive and calorimetric biosensors
Acoustic and piezoelectric biosensors detect changes in mass. In piezoelectric designs, a mass change at a quartz crystal alters its frequency, which can be converted into a signal. The review describes these sensors as candidates for detecting tumor biomarkers, including systems used with PCR-amplified targets.
Calorimetric biosensors instead measure heat produced or absorbed during a reaction. Temperature changes can provide indirect information about the amount of a target, but this format is described as less widely used for cancer detection. Examples in the review include investigations using aptamers and gold nanoparticles to detect cancer cells.
Biomarker results need context
A detectable marker is not automatically a definitive diagnosis. The review highlights limitations in several established cancer biomarkers. Prostate-specific antigen (PSA), for example, can be elevated in conditions other than prostate cancer, and an elevated result does not always indicate a malignant tumor. Cancer antigen 125 (CA 125) may rise in non-cancerous conditions and can remain within the normal range in some patients with early-stage ovarian cancer. Other markers discussed include CA 15-3 for breast cancer monitoring, CA 19-9 in pancreatic and other cancers, alpha-fetoprotein (AFP) in hepatocellular carcinoma, and RCAS1 in relation to cancer progression and prognosis.
These examples underline why biosensor development involves more than selecting a sensitive transducer. The target’s clinical role, the possibility of non-cancer-related changes and the need to interpret results alongside other information all matter. A multi-marker approach may provide a broader measurement picture, but the source does not imply that any single sensor design removes the limitations of its biomarkers.
Practical implications for measurement design
For engineers and technical decision-makers evaluating biosensor concepts, the review points to several design considerations: define which biomarker or biomarkers need to be detected; match the recognition element and transducer to the target; consider whether a portable or point-of-care format is required; and determine whether the application calls for a single measurement or parallel detection. Sample handling and the ability to obtain a timely, interpretable result are also central to the intended workflow.
Cancer biosensors bring biological recognition and signal measurement together in a range of formats. Electrochemical devices are prominent, while optical, mass-sensitive and calorimetric approaches offer different ways to detect target interactions. Their practical promise lies in sensitive, potentially rapid and multi-marker analysis—but results depend on biomarker meaning as well as sensor performance. Understanding both sides of the measurement is essential when assessing how biosensors may contribute to cancer detection and treatment monitoring.